Hematology-Oncology
Ann Arbor VA Medical Center and
University of Michigan Medical School
Evidence-Based Guidance Updated 4 September 2007 Kemp B. Cease, M.D.

This resource provides access to materials protected by United States and/or international copyright law. It is intended to facilitate "fair use" by those with legitamate access to these works. Learn more about copyright and fair use.

Site-Specific Resources

NCI Guidance    
NCCN Guidelines   
Cancer-Matrix

Site   Treatment Regimen   Links Citation Order Template
Hematology            
Lymphoma            
  Non-Hodgkins          
    CHOP CHOP Abs PDF Armitage JO 1984
J Clin Oncol 2:898		 CHOP
  intermediate and high grade NHL Rituximab Rituximab Abs   Coiffler B 1998
Blood 92:1927 		Rituximab
  low grade/
follicular NHL		     Abs PDF McLaughlin P 1998
J Clin Oncol 16:2825
  
    RCHOP-Gela RCHOP-Gela Abs   Coiffler B 2002
New Engl J Med 346:235
 RCHOP-Gela
    ICE ICE Abs PDF Moskowitz CH 1999
J Clin Oncol 17:3776
 ICE
    RICE RICE Abs PDF Kewalramani T 2004
Blood 103:3684
 RICE
    CEPP CEPP Abs PDF Chao NJ 1990
Blood 76:1293
 CEPP
    CVP - oral cyclophosphamide CVP Cit   Bagley CM Jr 1972
Ann Intern Med 76:227
 CVP-po
        Abs   Hoppe RT 1981
Blood 58:592
  
    CVP - i.v. cyclophosphamide CVP-iv Abs PDF Marcus R 2005
Blood 105:1417		 CVP-iv
    RCVP RCVP Abs PDF Marcus R 2005
Blood 105:1417		 R-CVP
    ChlVPP ChlVPP Abs   Selby P 1990
Br J Cancer 62:279
 ChlVPP
        Abs   Int'l ChlVPP Trtmt Grp 1995
Ann Oncol 6:167
  
        Abs PDF Hancock BW 2001
Br J Cancer 84:1291		  
  Hodgkin's Disease          
    ABVD ABVD Abs   Bonadonna G 1975
Cancer 36:252		 ABVD
    MOPP MOPP Cmt   Canellos 2002
N Engl J Med 346:1417		 MOPP
        Abs   Canellos 1992
N Engl J Med 327:1478		 MOPP
               
Leukemia            
  AML, APL          
  Induction Daunorubicin 3 + 7
w/Cytarabine (Ara C) 100 mg/M2		 Daun3and7-100
 Abs   Wiernik PH 1992
Blood 79:313
 Daun3and7-100
    Daunorubicin 3 + 7
w/Cytarabine (Ara C) 200 mg/M2 		Daun3and7-200 Abs   Mayer RJ 1994
N Engl J Med 331:896		 Daun3and7-200
    Idarubicin 3 + 7 -
w/Cytarabine (Ara C) 100 mg/M2		 Ida3and7-100 Abs   Wiernik PH 1992
Blood 79:313		 Ida3and7-100
  Relapsed High-Dose Ara-C (cytarabine) -
12-dose age > 50 y		 HiDAC-12-2000 Abs PDF Karanes C 1999
Leuk Res 23:787		 HiDAC-12-2000
    High-Dose Ara-C (cytarabine) -
12-dose age < 51 y 		HiDAC-12-3000 Abs PDF Karanes C 1999
Leuk Res 23:787		 HiDAC-12-3000
    High-Dose Ara-C (cytarabine) -
intensive consolidation		 HiDAC-consolidation Abs   Mayer RJ 1994
N Engl J Med 331:896		 HiDAC-consolidation
        Abs PDF Karanes C 1999
Leuk Res 23:787		  
    MEC - mitoxantrone,
etoposide, int.-dose cytarbine 		MEC Abs PDF Amadori S 1991
J Clin Oncol 9:1210		 MEC
        Abs PDF Greenberg PL 2004
J Clin Oncol 22:1078		  
  APL ATRA, daunorubicin, cytarabine
45/60/200 		ATRA3+7-200 Abs PDF Fenaux P 1999
Blood 94:1192		 ATRA3+7-200
               
Other            
  CLL          
    FCR FCR Abs PDF Keating MJ 2005
J Clin Oncol 23:4079
 FCR
        Abs   Bergsagel DE 1979
New Engl J Med 301:743
  
    Fludarabine Fludarabine Abs   Rai KR 2000
New Engl J Med 343:1750		 Fludarabine
    Chlorambucil and Prednisone
 ChlorambPred-7day 11023504   Robak T 2000
Blood 96:2723
 ChlorambPred-7day
  Hairy Cell          
    Cladribine (2-CdA)
single agent		 Cladribine Abs   Chadha P 2005
Blood 106:241
 Cladribine
  ITP Vincristine - single agent Vincristine Abs   Sikorska A 2004
Clin Lab Haematol 26:407		 Vincristine
  Myeloma          
    Melphalan and Prednisone MelphalanPred Abs   Abramson N 1982
Ca Treat Rep 66:1273
 MelphalanPred
        Abs PDF Oken MM 1997
Cancer 79:1561		  
    VAD VAD 6546971   Barlogie B 1984
N Engl J Med 310:1353		 VAD
               
Site   Treatment Regimen   Links Citation Order Template
Oncology            
Head and Neck          
  larynx          
     organ preservation chemo/RT VA larynx Abs PDF VALCSG 91
NEJM 324:1685		  
      Forastiere Abs PDF Forastiere 03
NEJM 349:2091		 forastiere-larynx
      Brizel Abs PDF Brizel 98
NEJM 338:1798		 brizel
      Denis Abs PDF Denis 04
JCO 22:69		  
  hypopharynx          
    chemo/RT Lefebvre/EORTC Abs PDF Lefebvre 96
JNCI 88:890		  
      Brizel Abs PDF Brizel 98
NEJM 338:1798		 brizel
  nasopharynx          
    chemo+RT Al-Sarraf/Int0099 Abs   Al-Sarraf 98
JCO 16:1310		 al-sarraf
  multiple            
    5-FU+cisplat+RT Brizel Abs PDF Brizel 98
NEJM 338:1798 		 brizel
    chemo+RT Adelstein 2000 Abs PDF

Adelstein 00
Cancer 88:876

  
    chemo+RT Adelstein 2002 Abs PDF Adelstein 02
JCO 20:1405		  
    chemo+RT Adelstein 2003 Abs     cisrad
    capecitabine+cisplat+RT Kim 2005 Abs PDF Kim 05
Br J Cancer 93:1117		 CapCis
  post-op chemo+RT Cooper 2004 Abs     cisrad
   recurrent FU+cisplat Jacobs Abs   Jacobs 92
J Clin Oncol 10:257 		  
    FU+carbo           
    Taxol+cisplat Adamo Abs PDF Adamo 04
Oral Onc 40:525		  
Lung          
  Small Cell          
    chemo+RT (bid vs qd) Turrisi 1999 Abs PDF Turrissi  cisplatvp1
    cisplat+vp dose resp. Ihde 1994 Abs   Ihde 94
J Clin Oncol 12:2022		 cis-vp 
    carbo+vp Skarlos 2001 Abs PDF   carbo-vp
    Irino+cis vs cis+VP16 Noda Abs PDF Noda 02
NEJM 346:85		  
  NSCLC          
    chemo/RT review Ruff   PDF Ruff 03
Onc SE 1:18		  
  NSC, III chemo/RT          
    carbo+taxol induction->CRT Socinski/UNC Abs PDF Socinski 00
Cancer 89:534 		 unc-chemo-rt 
      Rosenman/UNC Abs PDF Rosenman 02
IJROBP 54:348		 unc-chemo-rt
    chemo+RT Sause   PDF Sauce 00
Chest 117:358 		  
    metaanalysis Pritchard 1996 Abs   Pritchard 96
Ann Int Med 125:723 		  
    carbo+taxol CRT (no induction) Vokes 2007 Abs PDF Vokes 07
JCO 25:1698 		 
  NSC, IV General Approach Ruff   PDF Ruff 03
Onc SE 1:18		  
    carbo+taxol (7/175) Kosmidis 1997 Abs   Kosmidis 00
Ann Onc 11:799		 carbo-tax7_175 beta
    carbo+taxol (6/200) Kosmidis 2002 Abs PDF Kosmidis 02
JCO 20:3578		 carbo-tax6_200
    gem+cisplat Scagliotti 2002 Abs PDF Scagliotti 02
JCO 20:4285 OS Curve  		  
    gem+cisplat Abratt 1997 Abs     gen-cis-abratt
    gemzar+taxol(1000/200) Kosmidis 2002 Abs PDF Kosmidis 02
JCO 20:3578		 gem-tax
    platinum regimens RCT Scagliotti 2002 Abs PDF Scagliotti 02
JCO 20:4285 OS Curve		  
    docetaxel+carboplatin Millward 2003 Abs PDF   doce-carbo
    docetaxel+gemcitabine Niho 2003 Abs PDF   doce-gem
    Iressa FDA        
      Public Citizen        
  Evaluation PET-CT Bradley 2004   PDF Bradley 04
IJROBP 59:78		  
    PET editorial Paulino 2004   PDF Paulino 2004
IJROBP 59:4		  
    PET in Oncology Czernin 2002   PDF Czernin 2002
Acta Med Austriaca 29:162		  
Esophagus          
    EUS Staging Rice 2003   PDF Rice 2003
JTCV Surg 125:1091		  
    TFC->FC+XRT->Surgery Swisher 2003   PDF Swisher 2003
IJROBP 57:120		  
    Pre-Op CisplatFU+RT Kleinberg 2003   PDF Kleinberg 2003
IJROBP 56:328		  
    Pre-Op ChemoRT of Adeno Ca Walsh 1996   PDF Walsh 96
NEJM 335:462		  
    Walsh f/u correspondence (various) 1997   PDF various 97
NEJM 336:374		  
    Meta-analysis

Urschel 2003

   PDF Urschel 2003
AJ Surg 185:538		  
    Meta-analysis (excludes MAGIC) Gebski 2007 Abs PDF Gebski 07
Lancet Onc 8:226 		 
    ChemoRT review Kleinberg 2007 Abs PDF Kleinberg 07
JCO 25:4110 		 
    Pre-Op Chemo, ChemoRT review Gebski07 Abs PDF Gebski 07
Lancet Onc 8:226 		 
    Celiac Axis Node Issues Frizzell 2003   PDF Frizzell 2003
AJCO 26:215		  
  Squamous INT 122 ChemoRT toxicity Minsky 1996 Abs PDF Minsky 96
JCO 14:149 		 
    Pre-Op Chemo (no RT) Kelsen 1998 Abs PDF Kelsen 98
NEJM 339:1979		  
    INT113 Pre-Op Chemo (no RT) Kelsen 2007 Abs PDF Kelsen 07
JCO 25:3719		  
    MRC Cis + 5FU pre-Op (no RT) MRC-OCWP 2002 Abs PDF MRCOCWP 02
Lancet 359:1727 		 
  Adeno MAGIC ECF pre & post op (no RT) Cunningham 2006 Abs PDF Cunningham 06
NEJM 		 
  Squamous ChemoRT->Surg v ChemoRT alone Bedenne 2007 Abs PDF Bedenne 07
JCO 25:1160 		 
  Induction CisTax->CisTaxRT->Surg
MSKCC 3-Step		 Bains 2002 Abs PDF Bains 02
J Thor CV Surg 124:270 		 
  Induction - Adeno CisFU->ChemoRT->Surg
IrinoDoceFU->ChemoRT->Surg		 Malaisrie 2006 Abs PDF Malaisrie 06
Cancer 107:967 		 
  Primary/Definitive CRT Primary ChemoRT Minsky 2006 Abs HTML Minsky 06
Oncology 20:497 		 
    INT0123 ChemoRT (50.4 v 64.8 Gy) Minsky 2002 Abs PDF Minsky 02
JCO 20:1167 		50.4: = efficacy, less tox
   unresectable RTOG 85-01 ChemoRT v RT Cooper 1999
Abs PDF Cooper 99
JAMA 281:1623 correspondence		 Herskovic
  rec/metastatic            
               
Stomach/GE Junction          
   adjuvant   MacDonald Abs PDF MacDonald 01
NEJM 345:725		  gastric-adj
  metastatic  Taxol+5FU Murad        
               
Pancreas          
   adjuvant  RT + 5FU PVI Mehta Abs PDF   fu-sens-rt 
      Whittington Abs     fu-sens-rt 
      Osti Abs      
  rec/metastatic gemcitabine Burris Abs      
    gemcitabine+capecitabine Hess Abs PDF Hess 03
JCO 21:66		 gem-cap
    gemcitabine+cisplat Phillip Abs PDF Philip 01
Cancer 92:569		 gem-cis
Liver, Bile Ducts   Liver        
Bile Duct
   confined sensFU+RT Whittington Abs      
     transplantation  Yoo    PDF Yoo 03
JCO 21:4329		  
Colon          
  adjuvant FL+Oxaliplatin Andre   PDF Andre 04
NIJM 350:2343		  
    5-FU+Levamisole, 12 month Moertel 1995 Abs      
     5-FU+Leuc, qDx5, 6 month O'Connell 1997 Abs     fuleuc-dx5-adj 
    5-FU+ Leuc, weekly

Wolmark 1993

 Abs     fuleuc-wk-adj
    Leucovorin 20 vs 500/M2 Jager 1996 Abs      
    Clinical Announcement 1991 NCI   PDF    
  liver exclusive ablation links        
  distant mets Review     PDF Coco 03
Onc SE CME 1:92		  
          PDF D'Entremont 03
Onc SE 6:155		  
    5-FU+Leuc, qDx5 Poon 1989 Abs     fuleuc-dx5-met 
    5-FU+ Leuc, weekly Jager 1996 Abs     fuleuc-wk-met
    FU PVI Hanson   PDF Hansen-96
JNCI 88:668		  
    Irinotecan Rothenberg   PDF Rothenberg 99
Cancer 85:786		 irino-6wk 
    Irinotecan Pitot 1997 Abs   Pitot 97
jco 15:2910		 irino-6wk 
    Irinotecan Ulrich-Pur 2001 Abs   Ulrich-Pur 01
Ann Oncol 12:1269		 irino-3wk 
    FU+Leuc+Irino Saltz Abs PDF Saltz 00
NEJM 343:905 		 irino-fuleuc-irl-saltz 
    FOLFOX4 Rothenberg Abs PDF Rothenberg 2003
JCO 21:2059		 folfox4
    Oxaliplatin toxicity mgmt Pederiva 2004 Abs   ASCO 04
abstract 282		 folfox4, capox-4wk
      Gamelin 2004 Abs   Gamelin 04
Clin Ca Res 10:4055		 folfox4, capox-4wk
    CapOx, dose-intense Scheithauer 2003 Abs PDF   capox-4wk
    Capecitabine+Oxaliplatin  Twelves    PDF Twelves 02
Onc 16 (12 Sup):22		  
    Avastin+5FU+Leuc (FLA) Kabbinavar Abs PDF Kabbinavar 03
JCO 21:60		 fuleuc-wk-met
avastin
    Avastin+Saltz (IFLA) Genentech info   PDF   avastin
    Avastin+Saltz (IFLA) Hurwitz Abs PDF Hurwitz 04
NEJM 350:2335		 irino-fuleu-ifl-saltz
avastin
    Capecitabine+Irinotecan Kim Abs PDF Kim 05
Acta Onc 44:230		 CapIri
    Capecitabine+Irinotecan   Abs Abs      
    Capecitabine vs 5-FU Cutsem   PDF Cutsem 04
BJCa 90:1190		  
Rectal          
   adjuvant   O'Connell 1994 Abs PDF O'Connell 94
NEJM 331:502		 rectal-adj
    Clinical Announcement 1991 NCI   PDF    
  neoadjuvant capecitabine/leucovorin + RT Kim   PDF Kim 02
IJROBP 54(2):403		  
    XELOX-RT Rodel   PDF Rodel 03
JCO 21:3098		  
  metastatic  see colon above          
Anal          
   definitive   Flam 1996 Abs PDF  Flam 96
JCO 14:2527		 flam-anal 
               
Kidney          
                
               
Bladder          
     MVAC Loehrer        
    Gem+Cis Kaufman 2000 Abs PDF Kaufman 00
J Clin Oncol 18:1921		 gem-cis-kaufman
    Gem+Cis Moore   PDF  Moore 99
JCO 17:2876		 gem-cis-moore 
    Gem+Cis vs MVAC  von der Maase   PDF  von der Maase 00
JCO 17:3068		  
Prostate           
   localized            
  D1            
  PSA Failure definition ASTRO 2003 Web Print CancerConsultants.com  
  D2 hormonal Samson   PDF   zoladex 
      ASCO 2004 Web Print CancerConsultants.com  
    Docetaxel+Prednisone Eisenberger 2004 Abs   Eisenberger 04
ASCO abstract No.4

doce-pred
    Mitoxantrone+Prednisone Tannock 1996 Abs   Tannock 96
JCO 4:1756

mitoxan-pred
  D3 emcyt+VP Pienta Abs PDF Pienta 97
Urology 50:401		  
  D3 Taxane-based Saverese        
    pamidronate Small   PDF Small 03
JCO 21:4277		  
Testicular          
     PEB Loehrer 1995 Abs PDF Loehrer 95
JCO 13:470 		 peb 
               
Breast          
   adjuvant            
  locally adv.            
  metastatic CMF Harper-Wayne        
    CAF Stewart        
    Her2+Taxol Slamon   PDF    
    Her2+Taxol Seidman   PDF    
  male          
               
GYN             
  Ovarian          
  Epithelial          
  Germ
Low MP
          
  Endometrial          
  Cervical          
               
               
Brain           

 

 glioma PCV MRC-BTWG   PDF MRC-BTWP 01
JCO 19:509 		  
    correspondence re: above Chamberlain   PDF Chamberlain 01
JCO 19:3997 		  
    PCV Levin Abs   Levin 80
Ca Treat Rep 64:237		 pcv
  oligodendro PCV Diabira   PDF Diabira 01
JNeuro-Onc 55:45 		  
    TMZ van den Bent   PDF van den Bent 01
Neuro 57:340 		  
               
Skin          
   Melanoma, adjuvant IFN alpha-2b, adjuvant Kirkwood Abs PDF Kirdwood 00
JCO 18:2444		  
      Kirkwood Abs PDF Kirkwood 01
JCO 19:2370		  
      Kirkwood Abs PDF Kirkwood 04
Clin Ca Res 10:1670		  
      Sabel and Sondak Abs PDF Sabel 03
The Oncologist 8:451		  
  Melanoma, node neg IFN alpha-2b, IL2 adjuvant Hauschild        
  Melanoma, recurent   High Dose IL2 Atkins    PPT PowerPoint presentation to
National Academy of Sciences 		  
Sarcoma          
   Soft Tissue Doxorubicin+Ifosfamide Le Cesne 2000 Abs PDF Le Cesne 00
JCO 18:2676		  dox-ifos
    MAID Antman   PDF Antman 98
Cancer 82:1288 		  
  Osteosarcoma          
Unknown Primary            
    TFL (vs Cisplat+VP16) Dowell        

The Heme-Onc Resouce page is continuously revised and updated.
Please send comments and suggestions to: